

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

16th July, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i>	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East , Mumbai 400 051. <i>Scrip Symbol: ALKEM</i>
---	---

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”).

Dear Sir(s)/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, this is to inform you that the Company has acquired 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share aggregating to Rs. 11,00,00,00,005/- (‘Rights Shares’) offered by Alkem Medtech Private Limited, a wholly owned subsidiary of the Company in India (‘Alkem Medtech’), on a rights basis. The Company has been allotted aforesaid Rights Shares by Alkem Medtech on 15th July, 2026.

In this regard, the necessary disclosures/ information required to be submitted pursuant to Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026, have been provided in Annexure – I. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations.

Request you to kindly take the same on record.

Sincerely,

For Alkem Laboratories Limited

Manish Narang

President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

Particulars	Remarks
Name of the target entity, details in brief such as size, turnover etc.:	Alkem Medtech Private Limited, a wholly owned subsidiary of the Company ("Alkem Medtech") in India having a turnover of INR 15.13 crores for the financial year ended 31 st March, 2026.
Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms-length"	Acquisition does not fall within the purview of related party transaction.
Industry to which the entity being acquired belongs	Medical Device
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG.
Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
Indicative time period for completion of the acquisition	Equity shares were allotted on 15 th July, 2026.
Consideration- whether cash consideration or share swap and details of the same	Cash consideration.
Cost of acquisition or the price at which the shares are acquired;	Rs. 11,00,00,00,005/- 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share.
Percentage of shareholding / control acquired and/or number of shares acquired;	Alkem Medtech is a wholly owned subsidiary of the Company in India. Number of shares acquired : 79,36,50,794 equity shares at issue price of Rs. 13.86 per equity share.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Alkem Medtech was incorporated on 27 th March, 2024 under the provisions of the Companies Act, 2013. It is engaged in the business of medical device segment mainly in the cardiovascular and orthopedic fields. Turnover details: FY 2025-2026: INR 15.13 crores FY 2024-2025: INR NIL